New user fees could reverse efforts by the US FDA to increase generic drug availability and push drug prices down.
The agency announced the generic drug user fees for fiscal year 2018, the first year of GDUFA II, in a...
Generic User Fee Hikes Could Disrupt US FDA Drug Pricing Campaign
Listen to this article
New GDUFA program fee is high enough that sponsors may withdraw applications to reduce their fee exposure, agency estimates.
Learn what's happening at the US FDA. On the go.
More from US FDA
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
- • By
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
- • By
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
More from Agency Leadership
- • By
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
- • By
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
